HPGC Renmintongtai Pharmaceutical Corp Market Cap ($734.85 Million)
Market Cap & Net Worth: HPGC Renmintongtai Pharmaceutical Corp (600829)
HPGC Renmintongtai Pharmaceutical Corp market cap. HPGC Renmintongtai Pharmaceutical Corp (SHG:600829) has a market capitalization of $734.85 Million (CN¥5.02 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #9952 globally and #2585 in its home market, demonstrating a 1.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HPGC Renmintongtai Pharmaceutical Corp's stock price CN¥8.66 by its total outstanding shares 579888597 (579.89 Million). Also see 600829 cash flow metrics for how efficiently the company converts equity into cash flow.
HPGC Renmintongtai Pharmaceutical Corp Market Cap History (2015–2026)
HPGC Renmintongtai Pharmaceutical Corp market cap history from 2015 to 2026. Data shows change from $1.28 Billion to $734.85 Million (-1.87% CAGR). Check 600829 share price today for real-time trading data and today's change.
HPGC Renmintongtai Pharmaceutical Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HPGC Renmintongtai Pharmaceutical Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore HPGC Renmintongtai Pharmaceutical Corp annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.09x
HPGC Renmintongtai Pharmaceutical Corp's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.85x
HPGC Renmintongtai Pharmaceutical Corp's market cap is 6.85 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.17 Billion | $9.01 Billion | $224.51 Million | 0.13x | 5.23x |
| 2017 | $973.49 Million | $8.01 Billion | $254.20 Million | 0.12x | 3.83x |
| 2018 | $485.29 Million | $7.06 Billion | $257.86 Million | 0.07x | 1.88x |
| 2019 | $567.69 Million | $8.35 Billion | $267.33 Million | 0.07x | 2.12x |
| 2020 | $617.64 Million | $8.01 Billion | $145.26 Million | 0.08x | 4.25x |
| 2021 | $570.23 Million | $9.32 Billion | $277.30 Million | 0.06x | 2.06x |
| 2022 | $541.38 Million | $9.64 Billion | $264.48 Million | 0.06x | 2.05x |
| 2023 | $663.57 Million | $10.39 Billion | $292.16 Million | 0.06x | 2.27x |
| 2024 | $636.42 Million | $10.05 Billion | $213.27 Million | 0.06x | 2.98x |
| 2025 | $917.29 Million | $10.38 Billion | $133.84 Million | 0.09x | 6.85x |
Competitor Companies of 600829 by Market Capitalization
Companies near HPGC Renmintongtai Pharmaceutical Corp in the global market cap rankings as of November 8, 2026. Also see HPGC Renmintongtai Pharmaceutical Corp asset portfolio for a full breakdown of the balance sheet.
Key companies related to HPGC Renmintongtai Pharmaceutical Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of HPGC Renmintongtai Pharmaceutical Corp (2015–2026)
Market capitalization of HPGC Renmintongtai Pharmaceutical Corp from 2015 to today. Between 2015 and today, HPGC Renmintongtai Pharmaceutical Corp's market cap moved from $1.28 Billion to $ 734.85 Million, with a yearly change of -1.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥734.85 Million | -19.89% |
| 2025 | CN¥917.29 Million | +44.13% |
| 2024 | CN¥636.42 Million | -4.09% |
| 2023 | CN¥663.57 Million | +22.57% |
| 2022 | CN¥541.38 Million | -5.06% |
| 2021 | CN¥570.23 Million | -7.68% |
| 2020 | CN¥617.64 Million | +8.80% |
| 2019 | CN¥567.69 Million | +16.98% |
| 2018 | CN¥485.29 Million | -50.15% |
| 2017 | CN¥973.49 Million | -17.12% |
| 2016 | CN¥1.17 Billion | -8.01% |
| 2015 | CN¥1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of HPGC Renmintongtai Pharmaceutical Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $734.85 Million USD |
| MoneyControl | $734.85 Million USD |
| MarketWatch | $734.85 Million USD |
| marketcap.company | $734.85 Million USD |
| Reuters | $734.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more